Sign In
Buy KPTI
$9.00
-0.230 (-2.49%)
At Close: Jun 03, 2026
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
04:15pm, Wednesday, 03'rd Jun 2026
NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will parti
Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis Transcript
01:42pm, Wednesday, 03'rd Jun 2026
Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis Transcript
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
– New Data will Highlight a Post-Hoc Analysis from Phase 1 Portion of SENTRY Trial that Indicates Achievement of SVR35 with Selinexor plus Ruxolitinib May Predict Overall Survival – – Selected b
– Selinexor in Combination with Ruxolitinib Demonstrated a Rapid and Near Doubling of Patients Achieving SVR35 at Week 24, versus Ruxolitinib, with a Consistent SVR35 Benefit Observed Across Prespec
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 01'st Jun 2026
NEWTON, Mass., June 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company g
– Event To Feature Dr. John Mascarenhas, Principal Investigator of the Phase 3 SENTRY Trial – – Conference Call Scheduled for Tuesday, June 2, 2026 at 2:00 p.m. ET – NEWTON, Mass.
Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference
07:30am, Thursday, 28'th May 2026
NEWTON, Mass., May 28, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's
Wall Street Analysts Think Karyopharm Therapeutics (KPTI) Could Surge 70.46%: Read This Before Placing a Bet
10:55am, Wednesday, 27'th May 2026
The consensus price target hints at a 70.5% upside potential for Karyopharm Therapeutics (KPTI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea
Karyopharm Therapeutics Inc. (KPTI) Q1 2026 Earnings Call Transcript
03:00pm, Thursday, 14'th May 2026
Karyopharm Therapeutics Inc. (KPTI) Q1 2026 Earnings Call Transcript
Karyopharm Therapeutics Q1 Earnings Call Highlights
01:10pm, Thursday, 14'th May 2026
Karyopharm Therapeutics NASDAQ: KPTI said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in endometr
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates
09:46am, Thursday, 14'th May 2026
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to a loss of $2.77 per share a year ago.
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
07:30am, Thursday, 14'th May 2026
– Completed Enrollment of Phase 3 XPORT-EC-042 Trial in Endometrial Cancer; Topline Data Expected Mid-2026 – – Phase 3 SENTRY Results Selected for Late-Breaking Oral Presentation at ASCO on June
Karyopharm to Participate at Upcoming Investor Conferences
07:30am, Tuesday, 12'th May 2026
NEWTON, Mass., May 12, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's
Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026
07:30am, Thursday, 07'th May 2026
-- Conference Call Scheduled for Thursday, May 14, 2026, at 8:00 a.m. ET -- NEWTON, Mass.
